O4 Hubs detail
O4 Detail Hero Banner


Reality check: New drugs will cost more

The trend toward complex biologic drugs continues

By Sumit Dutta, MD, Chief Medical Officer at Optum Rx | Published: July 2022

O4 2 Columns (1/2 - 1/2)
O4 1 Column (Full)
O4 Text Component

What's in the pipeline?

This Optum Rx Drug Pipeline Report issue highlights four drugs reflecting cutting-edge technologies and their expected approval times:

  • Multiple myeloma
  • Plaque psoriasis
  • Two gene therapy drugs that target ultra-rare orphan conditions

View report

Don't want to read the full report? Download the brief summary.

Download summary

Related content

O4 Complex Card

Will these 4 new drugs re-shape the market?

Get the latest in this quarter’s Drug Pipeline Insights Report.
O4 Complex Card

Rush to judgement?

An inside look at the FDA's prescription drug approval process.
O4 Complex Card

Will Diabetes Drugs Help Us Tackle Obesity?

Discover four things to know about new uses of GLP-1 drugs.